Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > COMPANIES ARE RACING! !?!?!?

<< Previous

Bullboard Posts

Next >>

Post by general360on Oct 01, 2021 4:50pm

425 Views

Post# 33954023

COMPANIES ARE RACING! !?!?!?

A COVID-19 pill could soon fill a gap in our pandemic response that vaccines can’t overcome (msn.com)

here's the first couple of bullets. note the first one, "Companies are racing to develop a pill that can treat COVID-19." Well, all companies except for ours!!!!!!!!!!!!!!!!

Companies are racing to develop a pill that can treat COVID-19.
Merck has been the first company to announce successful trial results, but more are on their way.
An effective, easy-to-take treatment could play a big role alongside vaccines.
See more stories on Insider's business page.